on ADOCIA (EPA:ADOC)
Adocia Progresse with AdoXLongTM and BioChaperone®
Adocia, a Lyon-based biopharmaceutical company, has announced the filing of a patent for its new AdoXLong™ platform, which prolongs the action of peptides for the treatment of diabetes and obesity. This innovation would allow patients to switch from weekly to monthly injections, thus improving therapeutic persistence.
The patent initially covers semaglutide, with promising results indicating potential efficacy for a monthly injection. The technology is compatible with a variety of metabolic peptides such as GLP-1 and GIP.
In parallel, Adocia is continuing the development of its BioChaperone® platform with two feasibility studies with anonymous pharmaceutical companies. This platform aims to stabilize and combine hormones to treat diabetes and obesity, thus strengthening its therapeutic offering.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ADOCIA news